Intranasal drug delivery to overcome the blood–brain barrier

Keywords: Drug delivery systems, Blood brain barrier, Drug modulation, Intranasal drug delivery system, Brain disorders

Abstract

The blood–brain barrier (BBB) displays strict, selective control of the passage of substances into the brain parenchyma due to the low permeability and large collection of transporters on the brain microvascular endothelial cells. Due to the restrictive nature of the BBB, pharmacotherapy of neurological disorders is greatly limited. As a result, a multitude of drug delivery systems (DDSs) has been developed, such as drug modification, BBB permeability modification, and bypassing the BBB. The intranasal drug delivery system (IDDS) appears to be the best approach to bypass the BBB and presents a non-invasive, relatively safe, and rapid method of delivering drugs to the brain. The IDDS is a promising approach for the delivery of therapeutic proteins and peptides to the brain. Further research is required to aid in the translation of preclinical results to the clinical setting.

Author Biographies

J De Carvalho, University of Pretoria

Department of Pharmacology, University of Pretoria, South Africa

M Balmith, University of Pretoria

Department of Pharmacology, University of Pretoria, South Africa

B T Flepisi, University of Pretoria

Department of Pharmacology, University of Pretoria, South Africa

Published
2021-11-30
Section
Review